Contralateral prophylactic mastectomy in the setting of breast cancer diagnosis and their insurance coverage in the United States

2021 ◽  
Author(s):  
Michael Ha ◽  
Ledibabari M. Ngaage ◽  
Marissa Klein ◽  
Annie Yang ◽  
Shannon M. Colohan ◽  
...  
2015 ◽  
Vol 13 (12) ◽  
pp. 436-441 ◽  
Author(s):  
Bilal Farooqi ◽  
Betsy Smith ◽  
Mudit Chowdhary ◽  
Susan Pavoni ◽  
Aadil Modi ◽  
...  

2007 ◽  
Vol 25 (33) ◽  
pp. 5203-5209 ◽  
Author(s):  
Todd M. Tuttle ◽  
Elizabeth B. Habermann ◽  
Erin H. Grund ◽  
Todd J. Morris ◽  
Beth A. Virnig

Purpose Many patients with unilateral breast cancer choose contralateral prophylactic mastectomy to prevent cancer in the opposite breast. The purpose of our study was to determine the use and trends of contralateral prophylactic mastectomy in the United States. Patients and Methods We used the Surveillance, Epidemiology and End Results database to review the treatment of patients with unilateral breast cancer diagnosed from 1998 through 2003. We determined the rate of contralateral prophylactic mastectomy as a proportion of all surgically treated patients and as a proportion of all mastectomies. Results We identified 152,755 patients with stage I, II, or III breast cancer; 4,969 patients chose contralateral prophylactic mastectomy. The rate was 3.3% for all surgically treated patients; 7.7%, for patients undergoing mastectomy. The overall rate significantly increased from 1.8% in 1998 to 4.5% in 2003. Likewise, the contralateral prophylactic mastectomy rate for patients undergoing mastectomy significantly increased from 4.2% in 1998 to 11.0% in 2003. These increased rates applied to all cancer stages and continued to the end of our study period. Young patient age, non-Hispanic white race, lobular histology, and previous cancer diagnosis were associated with significantly higher rates. Large tumor size was associated with a higher overall rate, but with a lower rate for patients undergoing mastectomy. Conclusion The use of contralateral prophylactic mastectomy in the United States more than doubled within the recent 6-year period of our study. Prospective studies are needed to understand the decision-making processes that have led to more aggressive breast cancer surgery.


JAMA Surgery ◽  
2018 ◽  
Vol 153 (6) ◽  
pp. 594 ◽  
Author(s):  
Sahael M. Stapleton ◽  
Tawakalitu O. Oseni ◽  
Yanik J. Bababekov ◽  
Ya-Ching Hung ◽  
David C. Chang

Author(s):  
Mary C. White ◽  
Marion (Mhel) H. E. Kavanaugh-Lynch ◽  
Shauntay Davis-Patterson ◽  
Nancy Buermeyer

Advances in breast cancer science, early detection, and treatment have resulted in improvements in breast cancer survival but not in breast cancer incidence. After skin cancer, breast cancer is the most common cancer diagnosis in the United States. Each year, nearly a quarter million U.S. women receive a breast cancer diagnosis, and the number continues to rise each year with the growth in the population of older women. Although much remains to be understood about breast cancer origins and prevention, action can be taken on the existing scientific knowledge to address the systemic factors that drive breast cancer risk at the population level. The California Breast Cancer Research Program funded a team at Breast Cancer Prevention Partners (BCPP) to convene leaders in advocacy, policy, and research related to breast cancer prevention from across the state of California. The objective was the development of a strategic plan to direct collective efforts toward specific and measurable objectives to reduce the incidence of breast cancer. The structured, innovative approach used by BCPP to integrate scientific evidence with community perspectives provides a model for other states to consider, to potentially change the future trajectory of breast cancer incidence in the United States.


Sign in / Sign up

Export Citation Format

Share Document